EyeGene (XKRX:185490) Accounts Payable & Accrued Expense : ₩1,066 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is EyeGene Accounts Payable & Accrued Expense?

EyeGene's quarterly accounts payable & accrued expense increased from Sep. 2024 (₩1,556 Mil) to Dec. 2024 (₩3,615 Mil) but then declined from Dec. 2024 (₩3,615 Mil) to Mar. 2025 (₩1,066 Mil).

EyeGene's annual accounts payable & accrued expense increased from Dec. 2022 (₩1,633 Mil) to Dec. 2023 (₩2,987 Mil) and increased from Dec. 2023 (₩2,987 Mil) to Dec. 2024 (₩3,615 Mil).

EyeGene Accounts Payable & Accrued Expense Historical Data

The historical data trend for EyeGene's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyeGene Accounts Payable & Accrued Expense Chart

EyeGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2,520.23

3,740.93

1,633.10

2,987.28

3,615.35

EyeGene Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															512.00	757.94	1,555.60	3,615.35	1,065.53

EyeGene Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

EyeGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyeGene Inc (XKRX:185490) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gangseo-gu, Seoul 401, B-dong 910 Gayang-dong, Seoul, KOR, 07528

Website

http://www.eyegene.co.kr

EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

EyeGene Headlines

No Headlines